Statins and Cognitive Side Effects: What Cardiologists Need to Know

Endocrinology and Metabolism Clinics of North America

Volumn 45, Issue 1, 2016, Pages 101-116

  Rojas Fernandez, Carlos ^a,b   Hudani, Zain ^a   Bittner, Vera ^c  

^a UNIVERSITY OF WATERLOO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c University of Alabama at Birmingham   (United States)

Author keywords

Adverse drug effects; Cognition; Drug safety; Iatrogenesis; Memory; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOLOGIST; COGNITION; COGNITION ASSESSMENT; COGNITIVE DEFECT; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IATROGENIC DISEASE; INCIDENCE; META ANALYSIS (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK MANAGEMENT; SELF REPORT; SYSTEMATIC REVIEW (TOPIC);

EID: 84958171895     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2015.09.007     Document Type: Review

References (71)

1. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003, 2(7):517-526.
2. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380(9841):581-590.
4. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney P.M., Blackwell L., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371(9607):117-125.
5. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
6. Gu Q., Paulose-Ram R., Burt V.L., et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United states, 2003-2012. NCHS Data Brief 2014, (177):1-8.
7. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375(9716):735-742.
8. Rojas-Fernandez C.H., Goldstein L.B., Levey A.I., The National Lipid Association's Safety Task, Force, et al. An assessment by the statin cognitive safety task force: 2014 update. J Clin Lipidol 2014, 8(Suppl):S5-S16.
9. Rosenson R.S., Baker S.K., Jacobson T.A., The National Lipid Association's Muscle Safety Expert, Panel, et al. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol 2014, 8(Suppl):S58-S71.
10. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):2889-2934.
11. Padala K.P., Padala P.R., McNeilly D.P., et al. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012, 10(5):296-302.
12. Rojas-Fernandez C.H., Cameron J.C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012, 46(4):549-557.
13. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Available at:. Accessed November 6, 2013. http://www.fda.gov/drugs/drugsafety/ucm293101.htm.
14. Petersen R.C. Clinical practice. Mild cognitive impairment. N Engl J Med 2011, 364(23):2227-2234.
15. Feldman H., Levy A.R., Hsiung G.Y., et al. A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD): study methods and baseline results. Neuroepidemiology 2003, 22(5):265-274.
16. Hachinski V., Iadecola C., Petersen R.C., et al. National institute of neurological disorders and stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006, 37(9):2220-2241.
17. Tannenbaum C., Paquette A., Hilmer S., et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012, 29(8):639-658.
18. Neutel C.I., Morrison H., Campbell N.R., et al. Statin use in Canadians: trends, determinants and persistence. Can J Public Health 2007, 98(5):412-416.
19. Centers for Disease Control and Prevention. National center for health statistics. health, united states, 2010: With special feature on death and dying. Available at:. Accessed February 5, 2014. http://www.cdc.gov/nchs/data/hus/hus10.pdf.
20. Anderson S. Upbeat boomers say they're not old yet. USA today. July 14, 2011. Available at:. Accessed October 2, 2013. http://usatoday30.usatoday.com/news/health/healthcare/health/healthcare/prevention/story/2011/07/For-boomers-old-isnt-what-it-used-to-be/49375968/1.
21. Richardson K., Schoen M., French B., et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013, 159(10):688-697.
22. Swiger K.J., Manalac R.J., Blumenthal R.S., et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013, 88(11):1213-1221.
23. McGuinness B., O'Hare J., Craig D., et al. Cochrane Review on 'statins for the treatment of dementia'. Int J Geriatr Psychiatry 2013, 28(2):119-126.
24. Kelley B.J., Glasser S. Cognitive effects of statin medications. CNS Drugs 2014, 28(5):411-419.
25. Tuccori M., Montagnani S., Mantarro S., et al. Neuropsychiatric adverse events associated with statins: Epidemiology, pathophysiology, prevention and management. CNS Drugs 2014, 28(3):249-272.
26. Miron V.E., Zehntner S.P., Kuhlmann T., et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 2009, 174(5):1880-1890.
27. Klopfleisch S., Merkler D., Schmitz M., et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 2008, 28(50):13609-13614.
28. Evans M.A., Golomb B.A. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009, 29(7):800-811.
29. Wagstaff L.R., Mitton M.W., Arvik B.M., et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23(7):871-880.
30. Saher G., Simons M. Cholesterol and myelin biogenesis. Subcell Biochem 2010, 51:489-508.
31. Dong W., Vuletic S., Albers J.J. Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res 2009, 50(10):2095-2102.
32. Deschaintre Y., Richard F., Leys D., et al. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009, 73(9):674-680.
33. Li J., Wang Y.J., Zhang M., et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011, 76(17):1485-1491.
34. Gorelick P.B. Statin use and intracerebral hemorrhage: evidence for safety in recurrent stroke prevention?. Arch Neurol 2012, 69(1):13-16.
35. Flint A.C., Kamel H., Navi B.B., et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012, 43(1):147-154.
36. Flint A.C., Kamel H., Navi B.B., et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology 2012, 78(21):1678-1683.
37. Blanco M., Nombela F., Castellanos M., et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007, 69(9):904-910.
38. Wood W.G., Eckert G.P., Igbavboa U., et al. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 2010, 1199:69-76.
39. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 2011, 68(11):1385-1392.
40. Jacobsen W., Kuhn B., Soldner A., et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000, 28(11):1369-1378.
41. Johnson-Anuna L.N., Eckert G.P., Keller J.H., et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005, 312(2):786-793.
42. Thelen K.M., Rentsch K.M., Gutteck U., et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 2006, 316(3):1146-1152.
43. Tsuji A., Saheki A., Tamai I., et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993, 267(3):1085-1090.
44. Saheki A., Terasaki T., Tamai I., et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994, 11(2):305-311.
45. Nezasa K., Higaki K., Matsumura T., et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002, 30(11):1158-1163.
46. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009, 30(3):337-352.
47. Zeevi N., Pachter J., McCullough L.D., et al. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 2010, 58(9):1749-1757.
48. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005, 19(1):117-125.
49. Harrison R.W., Ashton C.H. Do cholestrol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994, 37:231-236.
50. Kostis J.B., Rosen R.C., Wilson A.C. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994, 34:989-996.
51. Cutler N., Sramek J., Veroff A., et al. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol 1995, 39:333-336.
52. Gengo F., Cwudzinski D., Kinkel P., et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995, 18:209-214.
53. Santanello N.C., Barber B.L., Applegate W.B., et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997, 45:8-14.
54. Muldoon M.F., Barger S.D., Ryan C.M., et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
55. Gibellato M.G., Moore J.L., Selby K., et al. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med 2001, 72:805-812.
56. Muldoon M.F., Ryan C.M., Sereika S.M., et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004, 117:823-829.
57. Golomb B.A., Dimsdale J.E., White H.L., et al. Do Low Dose Statins Affect Cognition? Results of the UCSD Statin Study. Circulation 2006, 114. II-289.
58. Parale G.P., Baheti N.N., Kulkarni P.M., et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006, 62:259-265.
59. Summers M.J., Oliver K.R., Coombes J.S., et al. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 2007, 27:183-190.
60. Berk-Planken I., de Konig I., Stolk R., et al. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care 2002, 25:1250-1251.
61. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
62. Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
63. Jick H., Zornberg G.L., Jick S.S., et al. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
64. Hajjar I., Schumpert J., Hirth V., et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002, 57:M414-M418.
65. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002, 59:223-227.
66. Yaffe K., Barrett-Connor E., Lin F., Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002, 59:378-384.
67. Starr J.M., McGurn B., Whiteman M., et al. Life long changes in cognitive ability are associated with prescribed medications in old age. Int J Geriatr Psychiatry 2004, 19:327-332.
68. Agostini J.V., Tinetti M.R., Han L., et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007, 55:420-425.
69. Redelmeier D.A., Thiruchelvam D., Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ 2008, 179:645-652.
70. Glasser S.P., Wadley V., Judd S., et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol 2010, 33:280-288.
71. Benito-León J., Louis E.D., Vega S., et al. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 2010, 21:95-102.